HIV-1 subtype distribution and the problem of drug resistance

Genetic diversity is a hallmark of HIV-1 infection with regard to the expansion of distinct viral subtypes (clades A, B, C, D, E, F, G, K, and O) in different geographical regions. Here, we discuss the issues of HIV-1 sensitivity to antiretroviral drugs and drug resistance in the context of HIV-1 subtype diversity. Virtually all available evidence suggests that all subtypes of HIV display similar sensitivity to antiviral drugs, but viruses from some subtypes or geographical regions may occasionally have a greater propensity to develop resistance against certain drugs than other viral variants. In some situations, the types of mutations associated with resistance may vary, as a result of subtle differences among subtypes with regard to the genetic code. This consideration notwithstanding, drug resistance is unlikely to become a more serious issue in developing than developed countries, and there is an urgency to make anti-HIV drugs available to all who are in need.

[1]  M. Wainberg,et al.  Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. , 2002, Antiviral therapy.

[2]  J. Albert,et al.  Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. , 1998, AIDS research and human retroviruses.

[3]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[4]  M. Wainberg,et al.  Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. , 2002, Antiviral research.

[5]  S. Knapp,et al.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon , 1994, Journal of virology.

[6]  P. Sharp,et al.  A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[7]  J. Condra.  Virological and clinical implications of resistance to HIV-1 protease inhibitors. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[9]  J. Nkengasong,et al.  The puzzle of HIV‐1 subtypes in Africa , 1997, AIDS.

[10]  S. Eshleman,et al.  Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. , 2000, AIDS research and human retroviruses.

[11]  Brendan Larder,et al.  Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy , 2001, Journal of Virology.

[12]  J. Rockstroh,et al.  Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients , 1997, AIDS.

[13]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[14]  F. Vannberg,et al.  Molecular Cloning and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-Length Clones from Botswana , 1999, Journal of Virology.

[15]  K. Hertogs,et al.  High Prevalence of Genotypic and Phenotypic HIV‐1 Drug‐Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'lvoire , 2001, Journal of Acquired Immune Deficiency Syndromes.

[16]  J. Takehisa,et al.  Various types of HIV mixed infections in Cameroon. , 1998, Virology.

[17]  M. Quiñones-Mateu.  Recombination in HIV-1: Update and Implications , 2001 .

[18]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[19]  Gerald H. Learn,et al.  Genetic subtypes of HIV‐1 in the Philippines , 1998, AIDS.

[20]  F. Brun-Vézinet,et al.  HIV-1 group O sensitivity to antiretroviral drugs. , 1995, AIDS.

[21]  E. Arts,et al.  Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[22]  R. Salamon,et al.  6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial , 1999, The Lancet.

[23]  M. Wainberg,et al.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors , 2003, AIDS.

[24]  F. Brun-Vézinet,et al.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses , 1997, Journal of virology.

[25]  Yves Van de Peer,et al.  Molecular phylogeny of part of the env gene of HIV‐1 strains isolated in Côte d'lvoire , 1994, AIDS.

[26]  T. Merigan,et al.  Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.

[27]  H Hui,et al.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology , 1994, Journal of virology.

[28]  M. Essex,et al.  HIV-1 Subtypes and Recombinants , 2002 .

[29]  J. Takehisa,et al.  Genetic subtypes of HIV type 1 in Republic of Congo. , 2000, AIDS research and human retroviruses.

[30]  N. Deacon,et al.  The Explosive Human Immunodeficiency Virus Type 1 Epidemic among Injecting Drug Users of Kathmandu, Nepal, Is Caused by a Subtype C Virus of Restricted Genetic Diversity , 2000, Journal of Virology.

[31]  D. Ho,et al.  Enhanced Infectivity of an R5-Tropic Simian/Human Immunodeficiency Virus Carrying Human Immunodeficiency Virus Type 1 Subtype C Envelope after Serial Passages in Pig-Tailed Macaques (Macaca nemestrina) , 2000, Journal of Virology.

[32]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[33]  M. Peeters,et al.  Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. , 2000, AIDS research and human retroviruses.

[34]  J. Mullins,et al.  The evolving molecular epidemiology of HIV‐1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials , 1995, AIDS.

[35]  F. Brun-Vézinet,et al.  Human Immunodeficiency Virus Type 1 Subtype F Reverse Transcriptase Sequence and Drug Susceptibility , 1998, Journal of Virology.

[36]  B Clotet,et al.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.

[37]  M. Peeters,et al.  Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994. , 1996, AIDS.

[38]  M. Peeters,et al.  High diversity of HIV-1 subtype F strains in Central Africa. , 1999, Virology.

[39]  Y. Takebe,et al.  The molecular epidemiology of HIV in Asia. , 1994, AIDS.

[40]  M. Becker,et al.  HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate. , 1993, AIDS.

[41]  J. Mascola,et al.  Multiple introductions of HIV-1 subtype E into the western hemisphere , 1995, The Lancet.

[42]  M. Wainberg,et al.  Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1 , 2005, Archives of Virology.

[43]  D. Gotte,et al.  Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. , 1996, AIDS research and human retroviruses.

[44]  F. Brun-Vézinet,et al.  Identification of a new human immunodeficiency virus type 1 distinct from group M and group O , 1998, Nature Medicine.

[45]  D. Pillay,et al.  Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. , 2002, The Journal of infectious diseases.

[46]  Remco,et al.  pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D , 1997, Journal of virology.

[47]  Groen,et al.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate , 1994, Journal of virology.

[48]  M. Salminen,et al.  HIV-1 in Ethiopia: Phylogenetic divergence from other HIV-1 strains , 1991, Virus Genes.

[49]  M. Peeters,et al.  Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. , 2000, AIDS research and human retroviruses.

[50]  R. Gilcher.  Human retroviruses and AIDS. , 1988, The Journal of the Oklahoma State Medical Association.

[51]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[52]  M. Essex.  State of the HIV pandemic. , 1998, Journal of human virology.